To determine whether apparent involvement of DYRK1A in Alzheimer’s disease (AD) pathology makes it a candidate plasma biomarker for diagnosis, we developed a method to quantify plasma DYRK1A by ...
Early identification of Alzheimer’s disease (AD) risk factors would aid development of interventions to delay the onset of dementia, but current biomarkers are invasive and/or costly to assess.
Alzheimer’s disease (AD) is a neurodegenerative condition. There are currently no FDA-approved disease‐modifying therapies for AD, despite it being the most common cause of dementia. AD is caused by ...
BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by ...
Entry of the SARS-CoV-2 virus into human tissues depends on the activity of a host gene that regulates production of a key viral receptor, according to a study publishing June 13 th in the open access ...
BOULDER, Colo., May 19, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by ...
GRAND RAPIDS, Mich. (WOOD) — A West Michigan mother is working to bring awareness to the impact of rare diseases after her 4-year-old son was diagnosed. Maverick Penley has a condition called DYRK1A ...
Research undertaken in recent years on Down’s syndrome has focused on the DYRK1A gene. The superexpression of this gene affects transmission in the neurones, according to Mr Garikoitz Azkona. In his ...
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 Acquisition includes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results